Investigations of Calsequestrin as a Target for Anthracyclines: Comparison of Functional Effects of Daunorubicin, Daunorubicinol, and Trifluoperazine
Authors:
- Richard D. OlsonRORichard D. Olson
- Carissa M. ThornockCTCarissa M. Thornock
- Wendy K. MercerWMWendy K. Mercer
- David R. OlsonDODavid R. Olson
- T. Stephen BroylesTBT. Stephen Broyles
- Dawn J. MuhlesteinDMDawn J. Muhlestein
- Corianton L. LarsonCLCorianton L. Larson
- Barry J. CusackBCBarry J. Cusack
- Susan E. ShadleSSSusan E. Shadle
- 1 May 2005
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 67 (5) , 1505-1512
Abstract
Anthracycline therapy is associated with a life-threatening but poorly understood cardiotoxicity. Effects of treatment are consistent with drug-induced disruption of cardiac sarcoplasmic reticulum (SR) calcium homeostasis, including inhibition of calcium release by anthracyclines. This effect, which depends on luminal SR calcium concentration, is hypothesized to involve interactions of anthracyclines with the calcium binding protein calsequestrin (CSQ). This study was designed to test the hypothesis that an interaction between CSQ and anthracyclines could be related to alterations in SR calcium release and cardiac function. The effects of the anthracycline, daunorubicin, and its metabolite daunorubicinol were compared with those of a known CSQ inhibitor, trifluoperazine (TFP). Protein fluorescence quenching studies demonstrated that TFP, daunorubicin, and daunorubicinol bind to CSQ with apparent binding affinities in the low micromolar range. The presence of calcium decreases the drug-dependent fluorescence quenching, probably because of calcium-induced CSQ conformational changes. TFP also inhibited SR calcium release. Although the TFP IC50 value is somewhat larger than for anthracyclines, the TFP effect is also dependent on luminal SR calcium concentration. In a muscle preparation, micromolar TFP decreased cardiac contractility in a manner that implicates the involvement of SR calcium and resembles the effects of anthracyclines. These data are consistent with a mechanism in which TFP or anthracyclines impair SR calcium release and cardiac function through a mechanism involving disruption of CSQ function. Such a mechanism may contribute to anthracycline cardiotoxicity.Keywords
This publication has 42 references indexed in Scilit:
- The Role of Calsequestrin, Triadin, and Junctin in Conferring Cardiac Ryanodine Receptor Responsiveness to Luminal CalciumBiophysical Journal, 2004
- Ser 16 -, but not Thr 17 -phosphorylation of phospholamban influences frequency-dependent force generation in human myocardiumPflügers Archiv - European Journal of Physiology, 2003
- Decreased Sensitivity of Neonatal Rabbit Sarcoplasmic Reticulum to Anthracycline CardiotoxicityCardiovascular Toxicology, 2002
- Head-to-tail oligomerization of calsequestrinJournal of Cell Biology, 2001
- Prevention by dexrazoxane of down‐regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the ratBritish Journal of Pharmacology, 2000
- Sarcoplasmic Reticulum Genes are Selectively Down-regulated in Cardiomyopathy Produced by Doxorubicin in RabbitsJournal of Molecular and Cellular Cardiology, 1998
- Daunorubicin-Induced Cardiac Injury in the Rabbit: A Role for Daunorubicinol?Toxicology and Applied Pharmacology, 1993
- Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbitCancer Chemotherapy and Pharmacology, 1993
- Effects of caffeine and ryanodine on depression of post‐rest tension development produced by Bay K 8644 in canine ventricular muscleBritish Journal of Pharmacology, 1989
- Control of interval‐force relation in canine ventricular myocardium studied with ryanodineBritish Journal of Pharmacology, 1988